JSPR – jasper therapeutics, inc. - class a (US:NASDAQ)
Stock Stats
News
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting
Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
Jasper Therapeutics to Present at Upcoming March Investor Conferences
Form EFFECT Jasper Therapeutics,
Form 424B5 Jasper Therapeutics,
Form 8-K Jasper Therapeutics, For: Mar 14
Form S-3 Jasper Therapeutics,
Form 10-K Jasper Therapeutics, For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.